Management of Hyperphosphatemia in Chronic Kidney Disease

Introduction to Hyperphosphatemia Management

The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend initiating phosphate-lowering treatment in patients with CKD G3a-G5D only for progressively or persistently elevated serum phosphate, starting with dietary phosphate restriction (800-1,000 mg/day), followed by phosphate binders when dietary measures fail, with calcium-based binders restricted in dose and avoided entirely in patients with vascular calcification, hypercalcemia, or suppressed PTH 1, 2, 3, 4

Treatment decisions should be based on serial assessments of phosphate, calcium, and PTH levels considered together, not isolated single values, as recommended by the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines 1, 5
The American College of Physicians recommends that normophosphatemia is no longer an indication to start phosphate-lowering treatments, reflecting evidence that preventing hyperphosphatemia may cause more harm than benefit, particularly with calcium-based binders in patients with normal phosphate levels 3, 4

Limit dietary phosphate intake to 800-1,000 mg/day as the initial approach for all patients with elevated phosphorus, adjusting based on protein needs to maintain adequate protein intake of 1-1.2 g/kg/day, as suggested by the National Kidney Foundation 6, 7
The bioavailability of phosphorus varies dramatically by source, guiding dietary recommendations: animal-based phosphate (40-60% absorbed), plant-based phosphate (20-50% absorbed), and inorganic phosphate in food additives (often >90% absorbed) 1, 3, 4, 5, 6

For CKD G3a-G4, start with calcium-based phosphate binders (calcium acetate or calcium carbonate) when serum phosphorus exceeds 4.6 mg/dL despite dietary restriction, limiting elemental calcium from binders to ≤1,500 mg/day and total calcium intake (including dietary) to not exceed 2,000 mg/day, as recommended by the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines 2, 4, 6, 7
For CKD G5D, either calcium-based binders or non-calcium binders can be used as primary therapy, but non-calcium binders should be strongly preferred in specific high-risk situations, such as severe vascular or soft-tissue calcifications, hypercalcemia, or suppressed PTH, according to the National Kidney Foundation 6, 7

If hyperphosphatemia persists (>5.5 mg/dL) despite monotherapy, combine calcium-based and non-calcium-based binders, which may yield additive benefits, as suggested by the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines 6

In patients with CKD G5D with persistent hyperphosphatemia despite binders, increase dialytic phosphate removal by considering more frequent or longer dialysis sessions, and use a dialysate calcium concentration between 1.25 and 1.50 mmol/l (2.5 and 3.0 mEq/l), as recommended by the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines 1, 2, 5, 6, 7

Maintain corrected total serum calcium in the normal range, preferably 8.4-9.5 mg/dL (lower end of normal) for dialysis patients, and avoid hypercalcemia in adult patients with CKD G3a-G5D, as recommended by the National Kidney Foundation 1, 5, 6, 7
Maintain Ca × P product <55 mg²/dL², as suggested by the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines 7

Patients with progressively rising or persistently elevated PTH above the upper normal limit should be evaluated for modifiable factors, including hyperphosphatemia, hypocalcemia, high phosphate intake, and vitamin D deficiency, and correcting hyperphosphatemia is a critical first step before addressing PTH directly, as recommended by the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines 1, 4, 5
For patients with CKD G5D, maintain intact PTH levels in the range of approximately 2-9 times the upper normal limit for the assay, and for those requiring PTH-lowering therapy, use calcimimetics, calcitriol, or vitamin D analogs, or a combination, as suggested by the National Kidney Foundation 1, 5

In children with CKD G3a-G5D, base the choice of phosphate-lowering treatment on serum calcium levels and maintain serum calcium in the age-appropriate normal range, as recommended by the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines 1, 2, 5

Do not use calcium-based binders in hypercalcemic patients or those with suppressed PTH (<150 pg/mL), as this worsens outcomes, and excess calcium exposure from calcium-based binders may contribute to cardiovascular calcification across all stages of CKD, as warned by the National Kidney Foundation 4, 6
Patients with vascular or valvular calcification should be considered at highest cardiovascular risk, and this information should guide management decisions—specifically favoring non-calcium binders, as recommended by the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines 1, 5
Overly aggressive PTH suppression can lead to adynamic bone disease, and normal or low PTH levels in ESRD may indicate adynamic bone disease, which is also problematic, as noted by the National Kidney Foundation 5